高级搜索
胡润, 姚沛, 李俊蒽, 桂仁捷, 段华新. 嵌合抗原受体NK细胞在淋巴瘤治疗中的研究进展[J]. 肿瘤防治研究, 2023, 50(12): 1243-1248. DOI: 10.3971/j.issn.1000-8578.2023.23.0664
引用本文: 胡润, 姚沛, 李俊蒽, 桂仁捷, 段华新. 嵌合抗原受体NK细胞在淋巴瘤治疗中的研究进展[J]. 肿瘤防治研究, 2023, 50(12): 1243-1248. DOI: 10.3971/j.issn.1000-8578.2023.23.0664
HU Run, YAO Pei, LI Junen, GUI Renjie, DUAN Huaxin. Research Progress of Chimeric Antigen Receptor NK Cells in Treatment of Lymphoma[J]. Cancer Research on Prevention and Treatment, 2023, 50(12): 1243-1248. DOI: 10.3971/j.issn.1000-8578.2023.23.0664
Citation: HU Run, YAO Pei, LI Junen, GUI Renjie, DUAN Huaxin. Research Progress of Chimeric Antigen Receptor NK Cells in Treatment of Lymphoma[J]. Cancer Research on Prevention and Treatment, 2023, 50(12): 1243-1248. DOI: 10.3971/j.issn.1000-8578.2023.23.0664

嵌合抗原受体NK细胞在淋巴瘤治疗中的研究进展

Research Progress of Chimeric Antigen Receptor NK Cells in Treatment of Lymphoma

  • 摘要: 过继细胞治疗是近年来肿瘤研究的热点,嵌合抗原受体T细胞(CAR-T)在血液肿瘤中已取得巨大成功,在一定程度上改变了目前肿瘤治疗格局,然而CAR-T疗法的严重不良反应及高昂的治疗费用限制了其在临床的使用范围。自然杀伤细胞(NK)是机体的重要免疫细胞,具有天然的细胞毒性及良好的安全性,基于CAR工程的NK细胞(CAR-NK)在临床前研究中已展现出强大的抗肿瘤活性及安全性,有潜力成为下一代基于CAR平台的免疫细胞疗法。本综述将系统介绍CAR-NK细胞在淋巴瘤中的研究现状。

     

    Abstract: Adoptive cell immunotherapy has been a hot spot in tumor research in recent years. Chimeric antigen receptor T cells (CAR-T) have achieved great success in hematological tumors and have changed the current tumor treatment landscape to a certain extent. However, the application of CAR-T therapy in clinics is limited due to its serious side effects and high treatment costs. Natural killer (NK) cells are important immune cells in the body and have native cytotoxicity and well safety. NK cells based on CAR engineering (CAR-NK) have shown powerful anti-tumor activity and safety in preclinical research and could be the next generation of CAR platform-based cellular immunotherapy. This review will systematically introduce the current research status of CAR-NK cells in lymphoma.

     

/

返回文章
返回